Officials on high alert as fatal brain-swelling meningitis spreads in Midwest and kills two

Public health officials in Chicago have issued an urgent alert for a severe, fast-moving bacterial infection that can attack ...
Pharmabiz

Daiichi Sankyo begins patient dosing in phase 1/2 trial of DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Daiichi Sankyo begins patient dosing in phase 1/2 trial of DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: Tokyo Friday, February 6, 2026, 10:00 Hrs [I ...

DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo

The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or ...
FierceBiotech

Fortitude has faith molecular glue degraders can overcome ADC resistance

What do you get when you insert a molecular glue degrader into an antibody-drug conjugate (ADC)? Fortitude Biomedicines is in the process of finding out. The Waltham, Massachusetts-based biotech is ...
ascopubs.org

Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study. Comparison of checkpoint inhibitor treatment-related cutaneous adverse ...